In line with the CEA's mission to develop innovative technologies and accelerate their transfer to industry, the event also aimed to engage with industry stakeholders, gather their perspectives, and better understand their needs in this complex and rapidly evolving field.
@CEA/Utopik
Four key themes were addressed:
- Perfusion & monitoring of O&OoC: Real-time monitoring of biological-on-a-chip models.
- From microfluidics to advanced microsystems: Instrumented and industrially scalable microfluidics for healthcare and NAMs (New Approach Methodologies).
- Organoid engineering: Organoid engineering for more mature 3D models that better representing physiopathology.
- Biomaterials and innovative matrices: The crucial role of biomaterials in the design of innovative matrices and alternatives to Matrigel.
In this expanding field, where each breakthrough opens up new possibilities for the evaluation and development of safer and more effective drugs, CEA reaffirms its commitment to a national strategy in partnership with the CNRS and Inserm through the “Organs and Organoids on Chips" (MED-OOC) research program, funded as part of the France 2030 plan.
These innovations are part of an initiative with a high societal impact, addressing critical major challenges related to technological sovereignty and industrial competitiveness. Organoids and organoids-on-a-chip represent a strategic focus area for the CEA, at the heart of the future of healthcare.